What were Marksans Pharma Ltd's latest quarterly results?
Marksans Pharma Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +63.7% (turning around (inflection up))
- Revenue Growth YoY: +20.9%
- Operating Margin: 23.0% (volatile)
Marksans Pharma Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +47.4%Strong4w Streak
In , Marksans Pharma Ltd (Pharma - Formulators) is outperforming Nifty 500 with +47.4% relative strength. Fundamentals: Strong. On a 4-week streak.
Marksans Pharma Ltd Key Facts
- PE Ratio
- 27.8x
- Market Cap
- ₹11,604 Cr
- PAT Growth YoY
- +64%
- Revenue Growth YoY
- +21%
- OPM
- 23.0%
- RS vs Nifty 500
- +47.4%
PE: Early ExpansionStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
🌐FII stake decreased 4.4% this quarter
🏛️DII accumulation — stake up 1.2%
💰Trading 21% above estimated fair value — significant premium
Key Numbers
PAT Growth YoY
+64%
Inflection Up
Revenue YoY
+21%
Stable
Operating Margin
23.0%
+500 bps YoY
PE Ratio
27.8
Current Price
₹256
Dividend Yield
0.31%
Fundamental Score
65/100
Strong
3Y PAT CAGR
+17%
Market Cap
11.6K Cr
Valuation
Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Marksans Pharma Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +21% | +17% | Stable |
| PAT (Net Profit) | +64% | +17% | Inflection Up |
| OPM | 23.0% | +500 bps | Volatile |
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Marksans Pharma Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Marksans Pharma Ltd's profit growing or declining?
Marksans Pharma Ltd's profit is growing with an turning around (inflection up) trend.
- PAT Growth YoY: +63.7% (latest quarter)
- PAT Growth QoQ: +30.7% (sequential)
- 3-Year PAT CAGR: +16.6%
- Trend: Turning around (inflection up) — consistent growth pattern
What is Marksans Pharma Ltd's revenue growth trend?
Marksans Pharma Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +20.9%
- Revenue Growth QoQ: +13.5% (sequential)
- 3-Year Revenue CAGR: +16.8%
How is Marksans Pharma Ltd's operating margin trending?
Marksans Pharma Ltd's operating margin is volatile.
- Current OPM: 23.0%
- OPM Change YoY: +5.0% basis points
- OPM Change QoQ: +2.0% basis points
What is Marksans Pharma Ltd's 3-year profit and revenue CAGR?
Marksans Pharma Ltd's long-term compounding rates
- 3-Year Profit CAGR: +16.6%
- 3-Year Revenue CAGR: +16.8%
Is Marksans Pharma Ltd's growth accelerating or decelerating?
Marksans Pharma Ltd's earnings growth is turning around (inflection up) with positive momentum on a sequential basis.
- YoY Acceleration: +55.1% bps
- Sequential Acceleration: +15.5% bps
What is Marksans Pharma Ltd's trailing twelve month (TTM) performance?
Marksans Pharma Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹420 Cr
- TTM PAT Growth: +9.7% YoY
- TTM Revenue: ₹3,000 Cr
- TTM Revenue Growth: +12.5% YoY
- TTM Operating Margin: 20.3%
Is Marksans Pharma Ltd overvalued or undervalued?
Marksans Pharma Ltd appears overvalued based on our fair value analysis.
- Valuation Signal: Overvalued
- Current PE: 27.8x
- Price-to-Book: 3.8x
What is Marksans Pharma Ltd's current PE ratio?
Marksans Pharma Ltd's current PE ratio is 27.8x.
- Current PE: 27.8x
- Market Cap: 11.6K Cr
- Dividend Yield: 0.31%
How does Marksans Pharma Ltd's valuation compare to its history?
Marksans Pharma Ltd's current PE is 27.8x.
- Current PE: 27.8x
- Valuation Assessment: Overvalued
What is Marksans Pharma Ltd's price-to-book ratio?
Marksans Pharma Ltd's price-to-book ratio is 3.8x.
- Price-to-Book (P/B): 3.8x
- Book Value per Share: ₹67
- Current Price: ₹256
Is Marksans Pharma Ltd a fundamentally strong company?
Marksans Pharma Ltd is rated Strong with a fundamental score of 65.31/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +20.9% (10% weight)
- PAT Growth YoY: +63.7% (10% weight)
- PAT Growth QoQ: +30.7% (10% weight)
- Margins stable (10% weight)
Is Marksans Pharma Ltd debt free?
Marksans Pharma Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹343 Cr
What is Marksans Pharma Ltd's return on equity (ROE) and ROCE?
Marksans Pharma Ltd's return ratios over recent years
- FY2024: ROCE 21.0%
- FY2025: ROCE 20.0%
- FY2026: ROCE 19.0%
Is Marksans Pharma Ltd's cash flow positive?
Marksans Pharma Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹458 Cr
- Free Cash Flow (FCF): ₹210 Cr
- CFO/PAT Ratio: 109% (strong cash conversion)
What is Marksans Pharma Ltd's dividend yield?
Marksans Pharma Ltd's current dividend yield is 0.31%.
- Dividend Yield: 0.31%
- Current Price: ₹256
Who holds Marksans Pharma Ltd shares — promoters, FII, DII?
Marksans Pharma Ltd's shareholding pattern (Mar 2026)
- Promoters: 43.9%
- FII (Foreign): 16.8%
- DII (Domestic): 6.6%
- Public: 32.8%
Is promoter holding increasing or decreasing in Marksans Pharma Ltd?
Marksans Pharma Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 43.9% (Mar 2026)
- Previous Quarter: 43.9% (Dec 2025)
- Change: 0.00% (stable)
How long has Marksans Pharma Ltd been outperforming Nifty 500?
Marksans Pharma Ltd has been outperforming Nifty 500 for 4 consecutive weeks, indicating building momentum.
Is Marksans Pharma Ltd a new momentum entry or an established outperformer?
Marksans Pharma Ltd is an established outperformer with 4 weeks of consecutive Nifty 500 outperformance.
Is Marksans Pharma Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Marksans Pharma Ltd may be worth studying
- Earnings growing at +63.7% YoY
- Cash flow is positive — CFO ₹458 Cr
What is the investment thesis for Marksans Pharma Ltd?
Marksans Pharma Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +20.9% YoY
Risk Factors (Bear Case)
- Appears overvalued
What is the future outlook for Marksans Pharma Ltd?
Marksans Pharma Ltd's forward outlook based on current data signals
- Earnings Trend: turning around (inflection up)
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.